ARCHIVES

New Cooperative Group Funded

This article is from The Cancer Letter archive.

Vol. 03 No. 39 | September 30, 1977

Download PDF Visit The Full Archive

Related Articles

ASCO Survey Finds Practice Expenses 90% Higher Than Medicare Assumptions

October 11, 2002

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

July 26, 2013

Breast Cancer Risk Prediction Improved In Atypia Cases

July 27, 2007

ODAC To Advise FDA on First Biosimilars Application Jan. 7

December 19, 2014

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

January 27, 2012

Survival For ALL Increased To 94 Percent In Recent Years

December 31, 2010